drugset
drugset / Trial / NCT05868356

A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib

NCT05868356 ↗

Phase 1 Completed 18 enrolled Mirati Therapeutics Inc.
Non-randomizedCrossoverOpen-labelOther

Summary

A Phase 1, Open-label, Multiple-dose, One-sequence Crossover Study to Investigate the Effect of Repeated Oral Doses of a Strong CYP2C8 Inhibitor on the Steady-state Pharmacokinetics of Adagrasib in Healthy Adult Subjects

Timeline

Start
2023-06-01
Primary completion
2023-07-25
Completion
2023-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Adagrasib Small molecule 200 mg Oral
Subject Gemfibrozil Small molecule 600 mg Oral

Indications

No indication recorded.